Warby Parker Inc
Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, single-vision lenses, progressive lenses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, travel cases, lenses cloth, anti-fog lens spray, and… Read more
Warby Parker Inc (WRBY) - Net Assets
Latest net assets as of September 2025: $369.62 Million USD
Based on the latest financial reports, Warby Parker Inc (WRBY) has net assets worth $369.62 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($706.92 Million) and total liabilities ($337.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $369.62 Million |
| % of Total Assets | 52.29% |
| Annual Growth Rate | 35.87% |
| 5-Year Change | 10.27% |
| 10-Year Change | N/A |
| Growth Volatility | 127.16 |
Warby Parker Inc - Net Assets Trend (2019–2024)
This chart illustrates how Warby Parker Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Warby Parker Inc (2019–2024)
The table below shows the annual net assets of Warby Parker Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $340.07 Million | +12.69% |
| 2023-12-31 | $301.79 Million | +5.28% |
| 2022-12-31 | $286.65 Million | +0.23% |
| 2021-12-31 | $286.00 Million | -7.27% |
| 2020-12-31 | $308.41 Million | +320.20% |
| 2019-12-31 | $73.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Warby Parker Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41775000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.00% |
| Other Comprehensive Income | $-1.94 Million | -0.57% |
| Other Components | $1.03 Billion | 302.65% |
| Total Equity | $340.07 Million | 100.00% |
Warby Parker Inc Competitors by Market Cap
The table below lists competitors of Warby Parker Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bellring Brands LLC
NYSE:BRBR
|
$2.12 Billion |
|
Ninestar Corp
SHE:002180
|
$2.12 Billion |
|
Kinetik Holdings Inc
NYSE:KNTK
|
$2.12 Billion |
|
Park National Corporation
NYSE MKT:PRK
|
$2.12 Billion |
|
Andon Health Co Ltd
SHE:002432
|
$2.12 Billion |
|
Hoshine Silicon Ind Co Ltd
SHG:603260
|
$2.11 Billion |
|
Adata Technology Co Ltd
TWO:3260
|
$2.11 Billion |
|
Acter Co Ltd
TWO:5536
|
$2.11 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Warby Parker Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 301,787,000 to 340,073,000, a change of 38,286,000 (12.7%).
- Net loss of 20,390,000 reduced equity.
- Other comprehensive income decreased equity by 409,000.
- Other factors increased equity by 59,085,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.39 Million | -6.0% |
| Other Comprehensive Income | $-409.00K | -0.12% |
| Other Changes | $59.09 Million | +17.37% |
| Total Change | $- | 12.69% |
Book Value vs Market Value Analysis
This analysis compares Warby Parker Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 35.80x to 8.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.66 | $23.59 | x |
| 2020-12-31 | $2.77 | $23.59 | x |
| 2021-12-31 | $2.52 | $23.59 | x |
| 2022-12-31 | $2.49 | $23.59 | x |
| 2023-12-31 | $2.57 | $23.59 | x |
| 2024-12-31 | $2.82 | $23.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Warby Parker Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.64%
- • Asset Turnover: 1.14x
- • Equity Multiplier: 1.99x
- Recent ROE (-6.00%) is above the historical average (-35.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -78.39% | -15.53% | 2.11x | 2.40x | $-64.88 Million |
| 2020 | -18.13% | -14.20% | 0.89x | 1.44x | $-86.76 Million |
| 2021 | -50.44% | -26.68% | 1.23x | 1.54x | $-172.87 Million |
| 2022 | -38.51% | -18.46% | 1.05x | 1.98x | $-139.06 Million |
| 2023 | -20.94% | -9.44% | 1.15x | 1.92x | $-93.38 Million |
| 2024 | -6.00% | -2.64% | 1.14x | 1.99x | $-54.40 Million |
Industry Comparison
This section compares Warby Parker Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Warby Parker Inc (WRBY) | $369.62 Million | -78.39% | 0.91x | $2.12 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |